Evaluating the validity of animal models for research into therapies for immune-based disorders

Bert A 't Hart, Sandra Amor, Margreet Jonker

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

The last few decades of the 20th century have shown an intensified search for safer and more effective medications against chronic diseases that burden ageing societies of the western world. The impressive development of biotechnological production techniques has greatly facilitated the pharmaceutical development of relatively non-toxic biological molecules. However, despite the huge investments, only a few effective therapies for immune-based diseases have reached the clinic. In this article we use examples from monoclonal antibody trials to discuss the validity and predictive strength of the animal models currently used for the development of effective therapies.

Original languageEnglish
Pages (from-to)517-24
Number of pages8
JournalDrug Discovery Today
Volume9
Issue number12
DOIs
Publication statusPublished - 15 Jun 2004

Cite this

@article{d2e2f80253a34aa0a0dfe66c822414c1,
title = "Evaluating the validity of animal models for research into therapies for immune-based disorders",
abstract = "The last few decades of the 20th century have shown an intensified search for safer and more effective medications against chronic diseases that burden ageing societies of the western world. The impressive development of biotechnological production techniques has greatly facilitated the pharmaceutical development of relatively non-toxic biological molecules. However, despite the huge investments, only a few effective therapies for immune-based diseases have reached the clinic. In this article we use examples from monoclonal antibody trials to discuss the validity and predictive strength of the animal models currently used for the development of effective therapies.",
keywords = "Adjuvants, Immunologic, Animals, Antibodies, Monoclonal, Arthritis, Rheumatoid, Disease Models, Animal, Drug Evaluation, Preclinical, Encephalomyelitis, Autoimmune, Experimental, Immune System Diseases, Immunotherapy, Multiple Sclerosis, Organ Transplantation, Comparative Study, Journal Article, Review",
author = "{'t Hart}, {Bert A} and Sandra Amor and Margreet Jonker",
year = "2004",
month = "6",
day = "15",
doi = "10.1016/S1359-6446(04)03112-5",
language = "English",
volume = "9",
pages = "517--24",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",
number = "12",

}

Evaluating the validity of animal models for research into therapies for immune-based disorders. / 't Hart, Bert A; Amor, Sandra; Jonker, Margreet.

In: Drug Discovery Today, Vol. 9, No. 12, 15.06.2004, p. 517-24.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Evaluating the validity of animal models for research into therapies for immune-based disorders

AU - 't Hart, Bert A

AU - Amor, Sandra

AU - Jonker, Margreet

PY - 2004/6/15

Y1 - 2004/6/15

N2 - The last few decades of the 20th century have shown an intensified search for safer and more effective medications against chronic diseases that burden ageing societies of the western world. The impressive development of biotechnological production techniques has greatly facilitated the pharmaceutical development of relatively non-toxic biological molecules. However, despite the huge investments, only a few effective therapies for immune-based diseases have reached the clinic. In this article we use examples from monoclonal antibody trials to discuss the validity and predictive strength of the animal models currently used for the development of effective therapies.

AB - The last few decades of the 20th century have shown an intensified search for safer and more effective medications against chronic diseases that burden ageing societies of the western world. The impressive development of biotechnological production techniques has greatly facilitated the pharmaceutical development of relatively non-toxic biological molecules. However, despite the huge investments, only a few effective therapies for immune-based diseases have reached the clinic. In this article we use examples from monoclonal antibody trials to discuss the validity and predictive strength of the animal models currently used for the development of effective therapies.

KW - Adjuvants, Immunologic

KW - Animals

KW - Antibodies, Monoclonal

KW - Arthritis, Rheumatoid

KW - Disease Models, Animal

KW - Drug Evaluation, Preclinical

KW - Encephalomyelitis, Autoimmune, Experimental

KW - Immune System Diseases

KW - Immunotherapy

KW - Multiple Sclerosis

KW - Organ Transplantation

KW - Comparative Study

KW - Journal Article

KW - Review

U2 - 10.1016/S1359-6446(04)03112-5

DO - 10.1016/S1359-6446(04)03112-5

M3 - Review article

VL - 9

SP - 517

EP - 524

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 12

ER -